Baillie Gifford & Co. Lowers Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

Baillie Gifford & Co. reduced its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 10.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 364,768 shares of the company's stock after selling 40,657 shares during the period. Baillie Gifford & Co. owned 0.43% of CRISPR Therapeutics worth $17,137,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. SFE Investment Counsel grew its stake in shares of CRISPR Therapeutics by 3.6% in the 2nd quarter. SFE Investment Counsel now owns 5,846 shares of the company's stock valued at $316,000 after buying an additional 203 shares during the period. Northwestern Mutual Wealth Management Co. grew its position in CRISPR Therapeutics by 4.8% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 4,606 shares of the company's stock worth $249,000 after acquiring an additional 211 shares during the period. Orion Capital Management LLC increased its stake in CRISPR Therapeutics by 44.0% during the first quarter. Orion Capital Management LLC now owns 720 shares of the company's stock worth $49,000 after acquiring an additional 220 shares during the last quarter. National Bank of Canada FI raised its position in CRISPR Therapeutics by 35.0% in the second quarter. National Bank of Canada FI now owns 848 shares of the company's stock valued at $46,000 after purchasing an additional 220 shares during the period. Finally, Larson Financial Group LLC lifted its stake in shares of CRISPR Therapeutics by 95.5% in the 2nd quarter. Larson Financial Group LLC now owns 565 shares of the company's stock valued at $31,000 after purchasing an additional 276 shares during the last quarter. 69.20% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 4,293 shares of the company's stock in a transaction on Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $198,680.04. Following the completion of the transaction, the chief executive officer now owns 226,540 shares in the company, valued at approximately $10,484,271.20. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other news, CEO Samarth Kulkarni sold 4,293 shares of CRISPR Therapeutics stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $198,680.04. Following the sale, the chief executive officer now owns 226,540 shares in the company, valued at approximately $10,484,271.20. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, General Counsel James R. Kasinger sold 1,089 shares of the company's stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $50,398.92. Following the completion of the sale, the general counsel now directly owns 62,597 shares of the company's stock, valued at approximately $2,896,989.16. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 35,382 shares of company stock worth $1,917,679 over the last three months. Insiders own 4.10% of the company's stock.

Wall Street Analyst Weigh In

CRSP has been the topic of several research analyst reports. Chardan Capital reduced their price objective on shares of CRISPR Therapeutics from $112.00 to $94.00 and set a "buy" rating on the stock in a report on Tuesday, August 6th. Cantor Fitzgerald reaffirmed a "neutral" rating on shares of CRISPR Therapeutics in a research report on Thursday, August 8th. Barclays cut their target price on CRISPR Therapeutics from $59.00 to $55.00 and set an "equal weight" rating on the stock in a research report on Wednesday, November 6th. Truist Financial lowered their price target on CRISPR Therapeutics from $120.00 to $100.00 and set a "buy" rating for the company in a research report on Monday, August 12th. Finally, Stifel Nicolaus cut their price objective on CRISPR Therapeutics from $60.00 to $59.00 and set a "hold" rating on the stock in a report on Tuesday, August 6th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Hold" and an average target price of $74.94.

CRISPR Therapeutics Price Performance

Shares of CRISPR Therapeutics stock traded down $0.94 during trading on Wednesday, hitting $49.79. 1,861,343 shares of the stock were exchanged, compared to its average volume of 1,470,891. The stock has a market cap of $4.25 billion, a price-to-earnings ratio of -17.60 and a beta of 1.67. The firm's 50-day moving average price is $47.70 and its 200 day moving average price is $52.14. CRISPR Therapeutics AG has a 12-month low of $43.42 and a 12-month high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.42) by $0.41. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. The business had revenue of $0.60 million during the quarter, compared to analysts' expectations of $6.65 million. During the same period in the prior year, the firm posted ($1.41) EPS. As a group, research analysts forecast that CRISPR Therapeutics AG will post -5.2 earnings per share for the current year.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.